Abstract

The present disclosure provides compositions and methods for enhanced healing of wounds, e.g. cutaneous wounds, by application of a scaffold or matrix, e.g. a hydrogel, comprising an effective dose of edited dendritic cells (DCs). As used herein, edited dendritic cells refers to mammalian, usually human, dendritic cells that have been genetically modified to alter expression of one or more genes involved in wound healing. In some embodiments edited DC are modified to downregulate or substantially eliminate expression of N-myc downregulated gene 2 (Ndrg2) expression, which cells may be referred to as Ndrg2 KO DCs.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/20 - Polysaccharides
• A61L 27/24 - Collagen
• A61L 27/52 - Hydrogels or hydrocolloids
• C08L 3/04 - Starch derivatives
• C08L 89/06 - Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A method for 3D object detection is described. The method includes predicting, using a trained monocular depth network, an estimated monocular input depth map of a monocular image of a video stream and an estimated depth uncertainty map associated with the estimated monocular input depth map. The method also includes feeding back a depth uncertainty regression loss associated with the estimated monocular input depth map during training of the trained monocular depth network to update the estimated monocular input depth map. The method further includes detecting 3D objects from a 3D point cloud computed from the estimated monocular input depth map based on seed positions selected from the 3D point cloud and the estimated depth uncertainty map. The method also includes selecting 3D bounding boxes of the 3D objects detected from the 3D point cloud based on the seed positions and an aggregated depth uncertainty.

IPC Classes  ?

• G06V 20/64 - Three-dimensional objects
• G06N 3/08 - Learning methods
• G06T 7/20 - Analysis of motion
• G06V 20/56 - Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle

Abstract

+1 +1 e00 f-1-1 g00) directly opposite the target adenosine to be edited when the antisense oligonucleotide is hybridised to the target nucleic acid, and (III) the following core sequence: 5'- a+4+4 b+3+3 c+2+2 d+1+1 e00 f-1-1 g-2-2 h-3-3 i-4-4 j-5-5 k-6-6 l-7-7 m-8-8 n-9-2-3-7-9-9+2+2).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

Systems and techniques for speech synthesis and analysis are illustrated. One embodiment includes a method that obtains a plurality of recordings corresponding to at least one vocalization, wherein each recording of the plurality of recordings includes a sensor measurement in a unique data modality that is obtained from a speaker during the at least one vocalization. The method encodes the plurality of recordings, using at least one encoder, into a shared latent space, wherein: each of the plurality of recordings includes a plurality of down-sampled timesteps where each corresponds to a distinct latent embedding. The method aligns the shared latent space, wherein, when the plurality of recordings is obtained concurrently: aligning the shared latent space includes temporally aligning the distinct latent embeddings across the plurality of encoded recordings using a cross-contrastive loss function. The method transduces the aligned latent space into synthesized speech.

IPC Classes  ?

• G10L 15/24 - Speech recognition using non-acoustical features
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G10L 15/22 - Procedures used during a speech recognition process, e.g. man-machine dialog
• A61B 5/372 - Analysis of electroencephalograms

Abstract

Compositions and methods are provided for the reversible modification of RNA to enhance RNA in-solution and enzymatic stability by reaction with acylimidazoles, sulfonyltriazoles, or sulfonylimidazoles. 2´-OH acylation protects RNA from hydrolytic and enzymatic degradation. Water-soluble organocatalysts can accelerate the reversal of acylation adducts and functionally restore RNAs, alternatively the acylation is spontaneously reversed in a cellular environment. Chemically tuned 2´-OH acylation can be spontaneously released in cells to restore RNA biological functions including translation. mRNA can be selectively modified at the 2´-OH of poly(A)-tail for enhanced in-cell stability and enhanced total protein output.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/33 - Heterocyclic compounds

Abstract

The present disclosure provides isothermally phase-separable elastin-like polypeptides (ELPs), the ELPs comprising: i) a first ELP domain having a first lower critical solution temperature (LCST); and ii) a second ELP domain having a second LCST that is different from the first LCST, wherein the first and second ELP domains are separated by an enzymatic cleavage site. Also included in the present disclosure are conjugates of the subject ELPs, nucleic acids encoding the subject ELPs, cells comprising nucleic acids encoding the subject ELPs, methods of use for the subject ELPs, and related kits.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 19/00 - Hybrid peptides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Abstract

Systems and methods for computing variation in physiological parameters and covariate relationships are provided. Sensor data derived can be transformed into physiological interval data. A point-process model with global optimization can be fit to the physiological interval data. Variation of the physiological interval data can be computed using the fitted model. Covariate data can also be collected. A state-space model with global optimization can be fit to the physiological interval data and covariate data.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/28 - Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
• A61B 5/346 - Analysis of electrocardiograms

Abstract

Provided is a high-speed variant ChRmine protein having faster kinetic properties compared to a parent ChRmine protein, where the high-speed variant ChRmine protein has one or more amino acid substitutions compared to the parent ChRmine protein. Also provided is a red-shifted variant ChRmine protein having a red-shifted spectrum compared to a parent ChRmine protein, where the red-shifted variant ChRmine protein has one or more amino acid substitutions compared to the parent ChRmine protein. Further provided is a nucleic acid encoding for a variant ChRmine protein disclosed herein as well as a genetically modified cell comprising such nucleic acid. Additionally, provided is an optogenetic method that includes genetically modifying a subject to express in the subject's brain cells a variant ChRmine protein disclosed herein, applying stimulating light to the subject's brain, and imaging the subject's brain.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
• C12N 15/86 - Viral vectors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided is an optical modulator including a substrate, and a plurality of unit structures periodically on the substrate, one of the plurality of unit structures including a heater layer on a first surface of the substrate, an antenna on a first surface of the heater layer, the antenna including a phase change material, a passivation layer on the substrate, the heater layer, and the antenna, and a reflector on a second surface of the substrate opposite to the first surface of the substrate.

IPC Classes  ?

• G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
• G02F 1/29 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection

Abstract

Presenting antigens linked to commensal bacterial surface proteins results in a surprisingly high immune response triggered when the bacteria are applied to an epithelial surface of a mammal. In some embodiments, an antigenic polypeptide or immunomodulatory molecule can be expressed from bacteria as a fusion with a bacterial surface protein. In other aspects, a variety of ways are described for linking an antigenic molecule or immunomodulatory molecule to a bacterial surface protein, providing flexibility for linking a desired antigen to the bacterial surface protein.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 1/20 - BacteriaCulture media therefor
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• A61K 35/74 - Bacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed herein are bifunctional compounds that facilitate relocalization of a target protein, e.g., between subcellular compartments and/or organelles. Also disclosed herein are compositions comprising the compounds and methods of using the compounds, e.g., in treating disorders such as cancer and neurodegenerative diseases.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Chemical compounds have been designed specifically from Claudin-4 binder peptides (C4BP) for radiopharmaceuticals. Specifically, compounds and compositions integrating C4BP have been designed with the distinct application in pancreatic cancer detection and therapy. Embodiments are compounds having a peptide, spacer (or without spacer), and chelator where this compound binds to CLDN4. The compound can incorporate the metallic radioisotopes to produce radiopharmaceuticals. Applications for these compounds include diagnostic procedures, therapeutic interventions, and targeted delivery of radionuclides to tissues that express CLDN4. Methods detailed herein delineate the use of radiopharmaceutical with CPB for diagnosis, treatment, and targeted delivery within CLDN4 expressing tissues.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 17/02 - Peptides being immobilised on, or in, an organic carrier

Abstract

fLPP that is an increasing monotone function of the absolute value of each parameter. Applications involving sparsity inducing regularization of arbitrary Neural Networks are discussed. Empirical results indicate that these sparse solutions are usually superior to their dense counterparts in both accuracy and interpretability. This improvement in accuracy can often make Neural Networks competitive with, and sometimes superior to, state-of-the-art methods in the analysis of tabular data.

IPC Classes  ?

• G06N 3/082 - Learning methods modifying the architecture, e.g. adding, deleting or silencing nodes or connections
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/0985 - Hyperparameter optimisationMeta-learningLearning-to-learn
• G06N 3/045 - Combinations of networks
• G06F 17/00 - Digital computing or data processing equipment or methods, specially adapted for specific functions
• G06N 20/00 - Machine learning

Abstract

Provided are compounds in the form of copolymers derived from lipid-functionalized carbonate monomers and guanidinylated serinol monomers, which are useful for the delivery of nucleic acids to cells and tissues. Also provided are related compositions and methods.

IPC Classes  ?

• C08G 63/64 - Polyesters containing both carboxylic ester groups and carbonate groups
• A61K 9/51 - Nanocapsules
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes

Abstract

A method of producing a conductive nanoporous support, comprises: (i) producing an inorganic template by mixing and subjecting to high-energy ball milling an inorganic material and a powder selected from a carbonaceous material, a polymer, or a metal oxide; and (ii) coating the inorganic template with metal nanoparticles to obtain the nanoporous support. The invention further relates to a conductive nanoporous support, an electrolytic electrode, or gas diffusion electrode and an electrolytic cell or fuel cell.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture
• H01M 4/92 - Metals of platinum group

Abstract

A photo-curable composition includes a fluorinated monomer including cross-linkable functional groups, and a photoinitiator. Manufacturing methods using the photo-curable composition are provided.

IPC Classes  ?

• G03F 7/004 - Photosensitive materials
• G03F 7/20 - ExposureApparatus therefor
• G03F 7/32 - Liquid compositions therefor, e.g. developers

Abstract

Systems and methods for treatment verification and re-treatment with iboga alkaloids in accordance with embodiments of the invention are illustrated. One embodiment includes obtaining a first arterial spin labeling (ASL) scan of a patient's brain pre-treatment with an iboga-alkaloid for a neuropsychiatric condition, obtaining a second ASL scan of the patient's brain post-treatment, measuring changes in regional cerebral blood flow (rCBF) in a left orbitofrontal cortex, left insula, right cingulate cortex, and left putamen of the patient's brain based on the first ASL scan and the second ASL scan, determining that the treatment succeeded when either (i) rCBF increased by at least 0.1 in the left orbitofrontal cortex, or (ii) rCBF increased by any amount in the left orbitofrontal cortex and in at least two of the left insula, right cingulate cortex, and left putamen, and determining that the treatment failed when it is not determined that the treatment succeeded.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/026 - Measuring blood flow
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

Various systems and methods for treatment or assessment utilizing electrical stimulation or signal recording are provided. Generally, treatment or assessment is performed on nerves that are transnasally accessible. Devices can include one or more electrodes to provide electrical stimulation or signal recording. Electrodes can be disposed upon an inflatable balloon. The inflatable balloon can comprise a plurality apertures. The inflatable balloon can be configured to have a tubular shape. The inflatable balloon can be configured to be cordless.

IPC Classes  ?

• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

Compositions and methods are provided for enhancing restoration of functional deficits following ischemia-induced damage to the brain. It is shown herein the administration of a stanniocalcin 2 (STC2) agent after an incident of ischemia-induced damage to the brain is beneficial in the restoration of function.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A continuous backwash upflow media filter comprises a container having a conical bottom; a wastewater influent tube having an opening within the container; an effluent weir within the container and an effluent tube with an opening in the effluent weir; a reject weir within the container below the effluent weir and a reject tube with an opening in the reject weir; an inverted deflection cone within the container positioned below the opening of the wastewater influent tube forming an annular space between the inverted deflection cone and the conical bottom of the container; an airlift pipe having a lower opening below the inverted deflection cone and below the annular space; and a sludge lift tube having a lower opening inside the media-free cavity formed by the inverted deflection cone above the annular space and an upper opening adapted to discharge sludge out of the container.

IPC Classes  ?

• B01D 24/44 - Feed or discharge devices for discharging filter cake, e.g. chutes
• B01D 24/24 - Downward filtration, the container having distribution or collection headers or pervious conduits
• B01D 24/46 - Regenerating the filtering material in the filter

Abstract

A method for magnetic resonance imaging includes a) performing by an MRI scanner an MRI scan to acquire non-Cartesian k-space MRI acquisition data; b) estimating by the MRI scanner Cartesian k-space data from the non-Cartesian k-space MRI acquisition data, wherein the estimating comprises estimating each Cartesian k-space coordinate in the Cartesian k-space data from multiple neighboring non-Cartesian k-space coordinates using an ensemble of GRAPPA kernels, where each of the GRAPPA kernels is obtained from a non-linear model trained on calibration data from an MRI calibration scan; and c) reconstructing by the MRI scanner an MRI image from the estimated Cartesian k-space data.

IPC Classes  ?

• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

A molecular design principle utilizes a steric hindrance effect to tune the solvation structures of Li+ ions. By substituting the methoxy groups on DME with larger-sized ethoxy groups, the resulting 1,2-diethoxyethane (DEE) has weaker solvation ability and consequently more anion-rich inner solvation shells, both of which enhance interfacial stability at cathode and anode. According to certain additional aspects, the present embodiments relate to a family of fluorinated-1,2-diethyoxyethane (fluorinated-DEE) molecules that are readily synthesized in large scales to use as the electrolyte solvents. Selected positions on 1,2-diethyoxyethane (DEE, distinct from the diethyl ether are functionalized with various numbers of fluorine atoms through iterative tuning, to reach a balance between CE, oxidative stability, and ionic conduction. Paired with 1.2 M lithium bis(fluorosulfonyl)imide (LiFSI), these fluorinated-DEE-based, single-salt single-solvent electrolytes are thoroughly characterized. In addition, a family of fluorinated ethyl methyl carbonates are designed and synthesized. Different numbers of F atoms are finely tuned to yield monofluoroethyl methyl carbonate (F1EMC), difluoroethyl methyl carbonate (F2EMC) and trifluoroethyl methyl carbonate (F3EMC). The cycling behavior of several types of lithium-ion pouch cells were systematically investigated to understand the impact of fluorination degree.

IPC Classes  ?

• H01M 10/0569 - Liquid materials characterised by the solvents
• C07C 43/12 - Saturated ethers containing halogen
• C07C 69/96 - Esters of carbonic or haloformic acids
• H01M 10/052 - Li-accumulators
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0568 - Liquid materials characterised by the solutes

Abstract

Adjustable aortic annuloplasty rings are disclosed for constricting a valve annulus, comprising an annular body sized for positioning around an exterior of the valve annulus, the annular body comprising a compliant uni-body driven by a Bowden cable constriction mechanism to adjust an inner diameter of the device.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

Provided are glycoprotein-active cathepsins, e.g., mucin-active cathepsins. According to some embodiments, the glycoprotein-active cathepsins are stably associated with a targeting moiety. In some instances, the glycoprotein-active cathepsin is stably associated with the targeting moiety via fusion of a protein domain comprising the glycoprotein-active cathepsin and a protein domain comprising the targeting moiety. In other embodiments, the glycoprotein-active cathepsin is stably associated with the targeting moiety via conjugation. In yet other embodiments, the glycoprotein-active cathepsin is stably associated with the targeting moiety via a non-covalent interaction. Also provided are methods of treating a glycoprotein-associated condition in a subject in need thereof, such methods comprising administering to the subject an effective amount of a glycoprotein-active cathepsin of the present disclosure. Upon administration of the glycoprotein-active cathepsin to the subject, the targeting moiety targets the glycoprotein-active cathepsin to cell surface, extracellular and/or secreted glycoproteins (e.g., mucins), and the glycoprotein-active cathepsin degrades the glycoproteins.

IPC Classes  ?

• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Compositions and methods are provided for ultrasound-triggered drug release that enables high drug loading potential for varied drugs of interest, has minimal drug release without ultrasound, can be activated following intravenous administration, and utilizes an ultrasound-activation mechanism that is mechanically-based, without requiring heating above body temperature or cavitation, and is activated with a low duty cycle and shorter ultrasound protocol than is used for heat or sonodynamic activation. These parameters are accomplished by tuning the acoustic impedance and osmolarity of the liquid core of an acoustically activatable particle, e.g. liposomes or emulsions, to maximize ultrasound responsiveness while maintaining overall stability of the structure in the absence of ultrasound.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61N 7/00 - Ultrasound therapy
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Compositions, methods, and kits are provided for diagnosing Parkinson's disease, vitreoretinal diseases, and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of Parkinson's disease and vitreoretinal diseases are also provided.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Methods and cell compositions are provided in which expression of one or more of the transcription factors are modulated to direct T cell phenotype and function, including differentiation of Tr1 cells. The resulting Tr1 cells are useful in the treatment of inflammatory and other conditions.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 15/1434 - Optical arrangements

Abstract

Methods of inhibiting a respiratory virus (i.e., a virus associated with a respiratory condition, e.g., influenza A, influenza B, RSV, etc.) are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region that find use in the subject methods. The oligonucleotides provided can include a 5-methylcytosine.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure relates to methods for selecting patients affected with cancer for treatment with a modified immune cell by obtaining a sample and detecting if the cells express one or more diagnostic transcriptional programs. The disclosure also relates to kits for detecting if the cell expresses one or more diagnostic transcriptional programs.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 5/078 - Cells from blood or from the immune system
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.

IPC Classes  ?

• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Compositions and methods are provided for induction and maintenance of quiescence of stem cells.

IPC Classes  ?

• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The present disclosure provides for methods and compositions useful for imaging inflammation and inflammatory disease markers with an affinity for TREM-1 antibodies. The methods and compositions can include a labeled probe having a TREM-1 antibody and a radiolabel.

IPC Classes  ?

• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Medical energy devices, systems, and methods that allows for treatment of systemic inflammatory disorders through modulation of neural activity.

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy

Abstract

Various embodiments of the present disclosure provide therapeutic compositions and associated methods for a cellular therapy comprising one or more cells, such as allogeneic cells, comprising a chimeric receptor and improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. In a preferred embodiment, the cellular therapy comprises (a) CD 19- and CD22-bispecific chimeric antigen receptor (CAR) T cells; (b) allogeneic hematopoietic stem cell transplant (HSCT) comprising one or more selected from: a population of CD34+ hematopoietic stem and progenitor cells (HSPCs), a population of conventional CD3+ T cells (Tcons), and a population of CD4+CD25+CD127dim regulatory T cells (Tregs), and/or a population of CD45RA- memor T cells Tmems.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Systems and methods for multichannel neuromuscular electrical stimulation in accordance with embodiments of the invention are illustrated. One embodiment includes a Multichannel Neuromuscular Electrical Stimulation (NMES) system, including multiple NMES Units, each NMES Unit including a processor, an input/output (I/O) interface capable of wireless communication, an inertial measurement unit (IMU), stimulation circuitry, and a memory storing a gait application, wherein each NMES Unit is configured by the gait application to collect IMU data using its on-board IMU, wirelessly distribute the IMU data to other NMES Units in the multiple NMES Units, identify gait events using a machine learning model, and deliver stimulation, if appropriate, in response to the identified gait events based on the position of the NMES Unit on a user's body.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G06N 3/02 - Neural networks
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Technology is provided for the production of collagen-based composite grafts with robust mechanical properties exceeding that of typical collagen hydrogels or foams. Collagen is a biodegradable and biocompatible hydrogel, but its clinical application is limited by poor mechanical properties that hinders its manipulation during surgeries and its post-surgical stability. The new collagen composite construct has robust mechanical properties for easy surgical handling such as rolling, suturing and passing a small surgical port during arthroscopic procedure, while maintaining unique biological characteristics of collagen matrix. Cells from various sources, bone marrow aspirate concentrates, growth factors, nanoparticles/microparticles (NPs/MPs), and supportive polymer meshes can be incorporated into the membranes for drug delivery and tissue regenerative therapies.

IPC Classes  ?

• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

In certain examples, methods and circuit-based apparatuses involve or are directed to a transducer to be operated via at least one resonance frequency of the transducer, and to a tunable circuitry (e.g., negative capacitance control and/or resistance control) to change the resonance frequency and/or a bandwidth around the resonance frequency. In more specific aspects, a tunable negative capacitance control may be used to change the resonance frequency and/or damping resistance control without degrading a degree of sensitivity provided by the transducer. Another example, specific to a method, involves: operating a transducer, coupled to a negative capacitance, at a resonance frequency of the transducer; and changing or setting a characteristic concerning the resonance frequency by using a tunable circuit to effect a change of the resonance frequency and/or a bandwidth around the resonance frequency.

IPC Classes  ?

• H04R 3/04 - Circuits for transducers for correcting frequency response
• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
• H04R 1/40 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only by combining a number of identical transducers
• H04R 3/12 - Circuits for transducers for distributing signals to two or more loudspeakers

Abstract

Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis

Abstract

An optical resonator includes a plurality of mirrors positioned to reflect light along a closed path, thereby defining an optical axis. The optical resonator also includes one or more intracavity lenses positioned along the optical axis to establish a resonator mode whose waist that is located along the optical axis. The optical resonator also includes an intracavity nonlinear optical element that implements a nonlinear frequency-mixing process within the optical resonator. When input light is coupled into the optical resonator to excite the resonator mode, the intracavity nonlinear optical element nonlinearly converts at least some of the input light into nonlinearly generated light. This nonlinearly generated light may then be coupled out of the optical resonator, such as via transmission through one of the mirrors. In some embodiments, the waist is five microns or less. In some embodiments, the finesse of the optical resonator is 100 or less.

IPC Classes  ?

• G02F 1/355 - Non-linear optics characterised by the materials used
• G02F 1/37 - Non-linear optics for second-harmonic generation
• G02F 1/39 - Non-linear optics for parametric generation or amplification of light, infrared, or ultraviolet waves
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A metastructure for use in communication systems, such as those operating in the microwave or millimeter wave frequency bands, is physically adapted to passively and simultaneously route, in multiple directions, multiple channels of an incoming signal. The metastructure can be incorporated into communication systems to improve their performance.

IPC Classes  ?

• G02F 1/355 - Non-linear optics characterised by the materials used
• H01Q 15/00 - Devices for reflection, refraction, diffraction or polarisation of waves radiated from an antenna, e.g. quasi-optical devices
• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
• B29C 64/10 - Processes of additive manufacturing
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

A method of ultrasound imaging includes a) performing a pulse-echo acquisition to produce channel signals using ultrasound transducers; b) processing transmitted and received channel signals to produce a dataset of a set of transmit elements and a set of receive elements; c) calculating an estimate of a critical imaging parameter; d) performing beamforming using the dataset and the estimate of the critical imaging parameter; e) calculating a desired loss function minimized with respect to the critical imaging parameter; f) differentiating the calculated loss function with respect to the critical imaging parameter by backpropagation; g) updating the estimate of the critical imaging parameter; h) repeating steps (d)-(g) until a convergence condition is satisfied; and i) generating an enhanced ultrasound image using the estimate of the critical imaging parameter.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• G01S 7/52 - Details of systems according to groups , , of systems according to group

Abstract

A method for magnetic resonance imaging with motion estimation comprises: a) performing with a magnetic resonance imaging apparatus a quantitative scout acquisition to produce a data acquisition sequence; b) predicting, based on the data acquisition sequence, navigator data throughout an entirety of the data acquisition sequence; and c) performing joint motion and δB0 estimation from the navigator data.

IPC Classes  ?

• G01R 33/567 - Image enhancement or correction, e.g. subtraction or averaging techniques gated by physiological signals
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

Abstract

Embodiments of the present disclosure pertain to a material that includes: (1) a first copper-based layer; (2) a copper nanowire layer above the first copper-based layer, which generally includes a plurality of copper nanowires embedded with a polymer; and (3) a second copper-based layer positioned above the copper nanowire layer such that the copper nanowire layer is sandwiched between the first copper-based layer and the second copper-based layer. Additional embodiments of the present disclosure pertain to methods of forming a material of the present disclosure.

IPC Classes  ?

• H01L 23/00 - Details of semiconductor or other solid state devices
• C25D 1/00 - Electroforming
• C25D 1/04 - WiresStripsFoils
• C25D 5/56 - Electroplating of non-metallic surfaces of plastics

Abstract

This disclosure relates to compositions and methods for treating ciliophathies.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• C12N 15/864 - Parvoviral vectors

Abstract

The disclosure includes compositions and pharmaceutical compositions and kits comprising novel brain progenitor cells. In some embodiments, the disclosure relates to methods of making the cell lines as well as methods of using the cell lines to perform functional assays while being manipulated in culture.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/074 - Adult stem cells

Abstract

Provided are inducible and repressible binding proteins based on α-helical repeat binding proteins. In certain embodiments, provided are polypeptides comprising an α-helical binding domain comprising a concave paratope, where the termini of the α-helical binding domain comprise a cross-paratope topology. The α-helical binding domain is flanked via flexible linkers by a caging domain pair switchable between an associated state in which the paratope is caged and a dissociated state in which the paratope is uncaged. In some instances, the caging domain pair is photoswitchable or chemoswitchable between the associated state and the dissociated state. Also provided are methods of using the polypeptides for conditional binding to a target molecule.

IPC Classes  ?

• C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
• C07K 1/00 - General processes for the preparation of peptides
• C07K 16/46 - Hybrid immunoglobulins
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Fabrication of metal compounds by combustion synthesis at lower temperatures is provided by primary fuel species that release a secondary fuel species when heated. Such secondary fuel species can be excellent fuels that reduce the required temperature for combustion synthesis. Secondary fuels produced in this manner are free of many of the constraints that usually govern fuel choice for combustion synthesis. For example, secondary fuels may not be able to form metal-complexes and/or they can be highly volatile.

IPC Classes  ?

• C01G 1/12 - Sulfides
• C01B 11/00 - Oxides or oxyacids of halogensSalts thereof
• C01B 21/00 - NitrogenCompounds thereof
• C01B 25/08 - Other phosphides
• C01G 1/02 - Oxides
• C01G 1/08 - Nitrates

Abstract

Provided are protease inhibitor compounds that find use in treating or preventing coronavirus disease. In some embodiments, the coronavirus disease is COVID-19. Also provided are compositions and kits comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus disease. Also provided are methods for reporting coronaviral protease inhibition.

IPC Classes  ?

• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 38/06 - Tripeptides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Compositions and methods are provided for the in vitro generation of functional human three-dimensional neural organizers that are functionally active and capable of choreographing in vitro midline brain development from human induced pluripotent stem cells (hiPSC). Demonstrated is a model of floor plate organizer ventral midline neurodevelopment, via the expression of a full compendium of axon guidance, morphogen, and cell signaling molecules. Floor plate organoids can be fused with spinal cord organoids into midline assembloids to induce specific cell fate and cell-cell interactions at the interface. This powerful platform can be used to model human neurodevelopment, study human genetic disorders that result from neural development, identify toxic molecules or drugs that disrupt midline brain development, and screen for therapeutics that could repair or rescue these defects.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/079 - Neural cells

Abstract

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

in vivoin vivo in effective amounts sufficient to promote new bone or cartilage growth. In addition, methods of screening for agonists, mimics, and analogues of CCN3 are also provided.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 19/00 - Drugs for skeletal disorders
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

Methods of reducing foreign body response (FBR) in a subject are provided. Aspects of the methods include implanting a foreign body, e.g., an implantable device, in the subject in combination with an effective amount of an SPP1 active agent, e.g., a SPP1 polypeptide, to reduce FBR in the subject. Also provided are implantable devices coated with a SPP1 active agent composition, e.g., a controlled release composition, and kits including an implantable device and a SPP1 active agent composition.

IPC Classes  ?

• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

We combine linear and nonlinear microscopy modalities. This approach is capable of imaging a sample using the two modalities concurrently, generating time sequences of images of the sample having different properties characteristic of each of the modalities. We can separate light emitted from the sample, generated by either modality, even if the spectrum of light is identical for each modality. The nonlinear microscopy modality allows one to create high resolution volumetric images of the sample. The concurrent imaging of the sample using linear and nonlinear microscopy modalities enables one to correlate a spatial structure and temporal dynamics of the sample acquired in each modality allowing one to create a mapping between images across the modalities. The created mapping can be used to match images of a tissue sample acquired using linear modality in a living organism with high resolution, two- or three-dimensional images obtained using nonlinear microscopy modality.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
• G02B 21/00 - Microscopes
• G02B 21/18 - Arrangements with more than one light-path, e.g. for comparing two specimens

Abstract

Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for concurrently measuring multiple biological parameters in an animal includes: a) illuminating using multiple illumination sources a region-of-interest of the animal that expresses a first genetically encoded fluorescent indicators (GEFI), a second GEFI, and a long-Stokes-shift (LSS) fluorescent compound that is insensitive to the multiple biological parameters; b) concurrently detecting fluorescence signals from the first GEFI, the second GEFI, and the LSS fluorescent compound using a multi-channel fluorescence sensing optical system; and c) processing the detected fluorescence signals to determine values of the multiple biological parameters, wherein the processing reduces instrument and/or biological artifacts in the values of the multiple biological parameters. The first and second GEFIs have distinct absorption spectra, where the first GEFI absorption spectrum overlaps the LSS fluorescent compound absorption spectrum, and the second GEFI emission spectrum overlaps the emission spectrum of the LSS fluorescent compound.

IPC Classes  ?

• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• G01N 21/64 - FluorescencePhosphorescence

Abstract

According to one aspect, a system for generating a reinforcement learning (RL) policy with guided meta RL is provided. The system may include a processor and a memory. The memory may store one or more instructions. The processor may execute one or more of the instructions stored on the memory to perform one or more acts, actions, and/or steps, such as generating an initial RL policy for an ego-vehicle based on an intelligent driver model (IDM), generating a set of RL guiding policies for a set of social agents based on the initial RL policy and a set of preferences, generating a meta-RL guided policy based on the set of RL guiding policies, and generating a RL policy with guided meta RL for the ego-vehicle based on the meta-RL guided policy and the IDM.

IPC Classes  ?

• B60W 60/00 - Drive control systems specially adapted for autonomous road vehicles
• G06N 3/092 - Reinforcement learning

Abstract

Disclosed herein are methods, systems and devices to model adaptive immune responses and develop and/or test improved antibodies, vaccines, and other therapeutic agents. The adaptive immune responses can be modeled using lymphoid tissue derived from a subject. The methods, systems and devices disclosed herein can comprise modified T-cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

Modular prosthetic valves are disclosed that may support a customized number of leaflets. e.g., four or more leaflets carried by a support structure, such as a frame or stent, which may be used to replace diseased mitral, aortic, tricuspid, or pulmonary valves.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

Improved fabrication of chalcogenide structures is provided by reacting a chalcogen gas with a transition metal structure. Optionally, the transition metal structure could be patterned before the reaction, which would result in a similarly patterned chalcogenide structure. In one example, we demonstrated rapid fabrication of multi-atomic layer WSe2 with good material quality. Such chalcogenides have various applications for optoelectronic devices, such as solar cells and photoelectrochemical cells.

IPC Classes  ?

• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C23C 8/06 - Solid state diffusion of only non-metal elements into metallic material surfacesChemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using gases
• C23C 14/58 - After-treatment
• C23C 14/14 - Metallic material, boron or silicon

Abstract

Compositions and methods are provided for immunizing an individual or population of individuals to generate an immune response that protects against pathogen infection in an antigen-agnostic manner. The protective antigen-agnostic immune response is active for a period of time following immunization, from about 7 days, 10 days, 14 days following immunization, and may be active for at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Compositions and methods are provided for treating ischemic conditions such as myocardial infarction, myocardial ischemia, or ischemia reperfusion injury in a subject in need thereof. In particular, the methods comprise administering a therapeutically effective amount of programmed death ligand-1 (PD-L1) to a subject.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Described is a locomotive implant for usage within a predetermined magnetic field. In one embodiment magnetohydrodynamics is used to generate thrust with a plurality of electrodes. In another embodiment, asymmetric drag forces are used to generate thrust.

IPC Classes  ?

• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 5/07 - Endoradiosondes
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• H02J 7/34 - Parallel operation in networks using both storage and other DC sources, e.g. providing buffering
• H02J 50/23 - Circuit arrangements or systems for wireless supply or distribution of electric power using microwaves or radio frequency waves characterised by the type of transmitting antennas, e.g. directional array antennas or Yagi antennas
• H02J 50/27 - Circuit arrangements or systems for wireless supply or distribution of electric power using microwaves or radio frequency waves characterised by the type of receiving antennas, e.g. rectennas
• H02J 50/80 - Circuit arrangements or systems for wireless supply or distribution of electric power involving the exchange of data, concerning supply or distribution of electric power, between transmitting devices and receiving devices
• H02J 50/90 - Circuit arrangements or systems for wireless supply or distribution of electric power involving detection or optimisation of position, e.g. alignment

Abstract

An apparatus for producing acid and base solutions from salt solutions is provided. An anode and a cathode are provided. A bipolar component is between the anode and the cathode. A first separator is between the bipolar component and the anode. A second separator is between the bipolar component and the cathode. A first salt solution flow passage is between the anode and the first separator. A second salt solution flow passage is between the first separator and the bipolar component. A third salt solution flow passage is between the bipolar component and the second separator. A fourth salt solution flow passage is between the second separator and the cathode.

IPC Classes  ?

• C25B 9/75 - Assemblies comprising two or more cells of the filter-press type having bipolar electrodes
• C25B 9/77 - Assemblies comprising two or more cells of the filter-press type having diaphragms
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 13/02 - DiaphragmsSpacing elements characterised by shape or form
• C25B 13/08 - DiaphragmsSpacing elements characterised by the material based on organic materials
• C25B 1/22 - Inorganic acids

Abstract

A method is provided comprising providing at least one of a calcium-containing salt and calcium-containing mineral. A silicate material that contains a ratio of O to Si greater than 2:1. A mixture of the at least one of the calcium-containing salt and the calcium-containing mineral and silicate material is heated to consume at least some at least one of the calcium-containing salt and the calcium-containing mineral and the silicate material to form a calcium-enriched silicate.

Abstract

Thrombectomy devices, systems, and methods are provided for performing thrombectomy procedures that include an aspiration catheter, a spinner device, and a source of vacuum, e.g., a pump for aspirating clot through the catheter. The spinner device includes a shaft including a proximal end coupled to a motor, a distal end earning a spinner head positionable in a lumen of the catheter for debulking and/or otherwise removing clot adjacent an outlet in a distal end of the catheter. The catheter may be introduced into a body lumen to posi tion the outlet adjacent a target clot, the source of vacuum may be activated, and, with the spinner head within the catheter adjacent the outlet, the motor may be activated to spin the spinner head to debulk and/or otherwise remove the clot through the catheter lumen around the spinner device.

IPC Classes  ?

• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 25/06 - Body-piercing guide needles or the like

Abstract

The present invention improves high-rate charge/discharge characteristics. This current collector assembly includes: an insulating substrate having a first main surface and a second main surface on the side opposite the first main surface; a positive-electrode current collector provided on the first main surface; and a negative-electrode current collector provided on the second main surface. The insulating substrate, the positive-electrode current collector, and the negative-electrode current collector are porous bodies.

IPC Classes  ?

• H01M 4/80 - Porous plates, e.g. sintered carriers
• H01M 4/66 - Selection of materials
• H01M 50/46 - Separators, membranes or diaphragms characterised by their combination with electrodes

Abstract

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.

IPC Classes  ?

• C07F 9/6512 - Six-membered rings having the nitrogen atoms in positions 1 and 3
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/69 - Boron compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07F 5/02 - Boron compounds
• C07F 9/60 - Quinoline or hydrogenated quinoline ring systems
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Abstract

The present invention relates to isolated and modified thrombopoietin polypeptides, uses thereof in expanding stem cells and producing platelets, and therapeutic applications of such modified thrombopoietin polypeptides, stem cells and platelets.

Abstract

Molecular electrocatalytic systems for ammonia production from wastewater nitrate are described. The electrocatalytic systems use ammonia-selective homogeneous molecular NOsRR catalysts in real wastewater.

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection
• C01C 1/18 - Nitrates of ammonium
• C01B 21/20 - Nitrogen oxidesOxyacids of nitrogenSalts thereof
• C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
• B01D 61/46 - Apparatus therefor
• C02F 1/70 - Treatment of water, waste water, or sewage by reduction
• C25B 1/27 - Ammonia
• C25B 11/073 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material

Abstract

The present invention provides recombineering-editing systems using CRISPR and recombination enzymes as well as methods, vectors, nucleic acid compositions, and kits thereof. The methods and systems provide means for altering target DNA, including genomic DNA in a host cell.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Transcriptomic changes induced by uptake of extracellular vesicles (EVs) are blocked or reversed by administration of an effective dose of Annexin V protein (AnxV), e.g. by administration of AnxV to a tumor microenvironment (TME). In some embodiments, administration of AnxV is combined with a second anti-cancer therapy. In some embodiments, cells present in the TME are evaluated for transcriptional changes associated with EV uptake following administration of the effective dose of AnxV.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

A medical device includes: an elongated member having a first end, a second end, and a body extending between the first end and the second end; a first anchor coupled to the first end of the elongated member; and a second anchor coupled to the second end of the elongated member; wherein the elongated member is configured for placement across an abdominal wall of a fetus, and wherein the elongated member is elastically stretchable to accommodate for a growing thickness of the abdominal wall of the fetus.

IPC Classes  ?

• A61M 27/00 - Drainage appliances for wounds, or the like
• A61M 25/00 - CathetersHollow probes
• A61M 25/04 - Holding devices, e.g. on the body in the body, e.g. expansible
• A61M 39/24 - Check- or non-return valves

Abstract

in vitroin vivoin vitroin vivoin vivo.

IPC Classes  ?

• C08G 64/02 - Aliphatic polycarbonates
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C08G 64/30 - General preparatory processes using carbonates
• C08G 63/64 - Polyesters containing both carboxylic ester groups and carbonate groups
• C08G 63/685 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing nitrogen

Abstract

The disclosure provides nucleic acid transporters in the form of copolymers derived from lipid carbonate monomers and cationic aminoester monomers prepared using various amino alcohol initiators, including linear and branched amino alcohol initiators, cyclic amino alcohol initiators and imidazole initiators. The compounds are useful for the delivery of nucleic acids to cells in vitro, ex vivo, or in vivo.

IPC Classes  ?

• C08G 63/64 - Polyesters containing both carboxylic ester groups and carbonate groups
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• C08G 63/685 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing nitrogen
• C08G 64/02 - Aliphatic polycarbonates
• C08G 64/30 - General preparatory processes using carbonates

Abstract

A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

IPC Classes  ?

• C08F 220/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules

Abstract

Methods are provided for the classification, diagnosis, and/or prognosis of an individual who has PD or is suspected to have PD. The method comprises obtaining one or more biological samples from an individual who has or is suspected to have PD, quantifying the amount of one or more PD-related polypeptides in the one or more biological samples wherein the one or more PD-related polypeptides comprises a Sulfate modifying factor 1 (SUMF1) polypeptide, and integrating the results of the quantifying step with the age and sex of the individual from whom the biological sample was obtained from to generate a metric that indicates if that individual has PD wherein the integration is performed by a computer comprising software components for data analysis as a program of instructions executable by the computer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

Compositions and methods for delivery of nucleic acid therapeutics are disclosed herein. In some embodiments, a composition for treating a subject includes a dynamic hydrogel, and a nucleic acid therapeutic encapsulated by the dynamic hydrogel. The dynamic hydrogel can include a polymer and a plurality of nanoparticles. The polymer can be non-covalently crosslinked with the plurality of nanoparticles.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/74 - Major histocompatibility complex [MHC]
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/86 - Viral vectors
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C40B 50/10 - Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creationParticular methods of cleavage from the liquid support involving encoding steps
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided are molecular sensors comprising a capture agent that binds to a first epitope of an analyte, and an aptamer that binds to a second epitope of the analyte. The aptamer is stably associated with the capture agent and produces a detectable signal upon cooperative binding of the capture agent and aptamer to the analyte. Also provided are substrates comprising a molecular sensor of the present disclosure immobilized on the surface thereof, as well as devices comprising the molecular sensors and substrates. Methods of using the molecular sensors, substrates and devices of the present disclosure are also provided. In some instances, the methods are for assessing a sample for an analyte, the methods comprising contacting a molecular sensor of the present disclosure with the sample under conditions suitable for cooperative binding of the capture agent and aptamer to the analyte, and assessing for a detectable signal produced by the aptamer.

IPC Classes  ?

• C12Q 1/6825 - Nucleic acid detection involving sensors
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present disclosure provides programmable synthetic receptor fusion proteins comprising an input module, a G-protein coupled receptor (GPCR), and an optional output module. The input module comprises a peptide inhibitor of a GPCR, an antigen binding molecule, and/or a linker which can contain a protease cleavage site. The optional output module can comprise a polypeptide having a) a light-sensitive voltage sensitive (LOV) domain, b) a tobacco etch virus protease recognition sequence (TEVcs), and c) a transcription factor (TF), where the polypeptide is covalently linked to the carboxy terminus of the GPCR. Antigen binding or protease cleavage activates the receptor, leading to either G protein mediated cell signaling, or cleavage of the TEVcs, which releases the TF and activates transcription of a target gene. Thus, the disclosure allows user programmed input signals to activate gene expression or intracellular signaling pathways.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

Composition and methods are provided for the treatment of a mammalian subject for axonopathies. Enhancing mitochondria axonal localization by overexpression of OPTN, TRAK1 and/or KIF5B promotes neuroprotection and axon regeneration, demonstrating a physiological role for OPTN as a stabilizer of the KIF5B-TRAK1 mitochondria transport complex to the microtubule. OPTN/TRAK1/KIF5B is provided herein as a therapeutic target for neuroprotection and axon regeneration for neurodegenerative diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/864 - Parvoviral vectors
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Methods of making fibrin mesh are described.

IPC Classes  ?

• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/38 - Animal cells
• A61L 27/50 - Materials characterised by their function or physical properties
• B33Y 10/00 - Processes of additive manufacturing

Abstract

Tissue engineering constructs and the method of making the constructs are provided. The constructs distinguish a scaffold with a surface and a treated surface area for increased surface area. A hydrophilic hydrogel network is physically cross-linked via charged polymers and salt-ions onto the treated surface area. Biologies is trapped and thereby hosted within the physically cross-linked hydrogel network. Covalently reactive macromonomers are chemically cross-linked within the physically cross-linked hydrophilic hydrogel network to strengthen the physically cross-linked hydrophilic hydrogel network itself and to the scaffold. The constructs enable delivery of therapeutics including cells and/or biomolecules along with a structural support and a defined geometry for applications in regenerative medicine.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/34 - Macromolecular materials
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

The present disclosure provides recombineering-editing systems using CRISPR and recombination enzymes as well as methods, vectors, nucleic acid compositions, and kits thereof. The methods and systems provide means for altering target DNA, including genomic DNA in a host cell.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

Wnt signaling antagonist and agonist compositions and methods for their use are provided.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

An orthogonal variant of human CD3e is provided, which orthoCD3e does not bind to an antibody of interest, e.g. antibodies having a binding specificity of OKT3, but which retains binding to cellular proteins CD3d and CD3g. T cells that are engineered to express the orthoCD3e express normal levels of the T cell receptor complex on their surface and have a functional T cell receptor complex. These engineered T cells are useful in therapeutic methods where it is desirable to lymphodeplete resident T cells from an individual while sparing transferred therapeutic T cells.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided are genetically modified mammalian cells with enhanced permissiveness to adeno-associated virus (AAV) infection. The cells have increased levels of AAVR protein and reduced levels of SETDB1 protein relative to a corresponding cell that is not genetically modified. Also provide are methods of AAV delivery and methods of AAV titration using such cells.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Abstract

In certain examples, methods and apparatuses (e.g., semiconductor structures) are directed to use of a ID fiber material characterized as a fibrous structure having one or more transformations from among: a spiral, a roll and wrinkles. Such an apparatus may include one or more wire-contact regions, adjacent and unconnected to the ID fiber material, for contacting the ID fiber material, and may include sensor circuitry (integrated with the ID fiber material) to sense parameters in response to changes in at least one of: pressure, capacitance, and strain. In a more specific example, such an apparatus includes a polymer- based substrate with one or more properties from among; a self-adhesive property', being stretchable; and an elasticity property with the ability to return to its original shape after being stretched.

IPC Classes  ?

• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof

Abstract

Core-shell nanoparticles having a relatively thin shell (< 50 nm thick) are provided for water treatment applications. These nanoparticles have metal cores, semiconductor shells, and are plasmon-resonant. The absorption spectra of such nanoparticles can be engineered to have high overlap with spectra of interest, such as the solar spectrum. The resulting nanoparticles can be used for purification and/or detection of contaminants in water, both biological and chemical.

IPC Classes  ?

• C02F 1/30 - Treatment of water, waste water, or sewage by irradiation
• C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
• G01N 21/65 - Raman scattering
• A61L 9/18 - Radiation
• B01J 35/39 - Photocatalytic properties
• B01J 35/45 - Nanoparticles
• B01J 35/53 - Spheres with a core-shell structure
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

A brain machine interface (BMI) to control a device is provided. The BMI has a neural decoder, which is a neural to kinematic mapping function with neural signals as input to the neural decoder and kinematics to control the device as output of the neural decoder. The neural decoder is based on a continuous-time multiplicative recurrent neural network, which has been trained as a neural to kinematic mapping function. An advantage of the invention is the robustness of the decoder to perturbations in the neural data; its performance degrades less—or not at all in some circumstances—in comparison to the current state decoders. These perturbations make the current use of BMI in a clinical setting extremely challenging. This invention helps to ameliorate this problem. The robustness of the neural decoder does not come at the cost of some performance, in fact an improvement in performance is observed.

IPC Classes  ?

• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/08 - Learning methods

Abstract

Methods and systems for constructing gene modules with regulator genes and target genes are provided. A Gaussian mixed model can construct gene modules using RNA sequencing data. Sets of gene modules can be compared to identify shared or unique biological processes.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A connector apparatus for an electric charging cable, such as for use with a charging station and an electric vehicle, the connector apparatus comprising: a connector block having a first end and a second end, the first end having one or more connectors configured to pass electrical energy through an electric cable; the electric cable having an end portion that is fixed within the connector block, the electric cable extending out of the connector block from the second end of the connector block and configured to transfer electric current; and a plurality of heat pipes having fixed ends fixed within the connector block and having exposed ends extending out of the second end of the connector block, the plurality of heat pipes configured to dissipate heat from the connector block through the exposed ends of the plurality of heat pipes.

IPC Classes  ?

• H01B 7/42 - Insulated conductors or cables characterised by their form with arrangements for heat dissipation or conduction
• B60L 53/18 - Cables specially adapted for charging electric vehicles
• B60L 53/302 - Cooling of charging equipment
• F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
• F28D 21/00 - Heat-exchange apparatus not covered by any of the groups

Abstract

ΥΥR expression on myeloid cells during administration of anti-CD47 antibodies to achieve improved therapies.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Compositions and methods for delivery of therapeutic peptides are disclosed herein. In some embodiments, for example, a composition for treating a disease or condition includes a dynamic hydrogel, and an acylated peptide encapsulated by the dynamic hydrogel. The dynamic hydrogel can include a polymer and a plurality of nanoparticles. The polymer can be non-covalently crosslinked with the plurality of nanoparticles.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/51 - Nanocapsules
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Described herein are methods, compositions, devices, and kits related to methods for 3-dimensional (3D) spatial single cell omics analysis based on the concept of spatial encoding by positional markers injected with implantation devices (for example, jetlet dispensors). Aspects of the present disclosure provide for at least the following: 1) single cell multiomics: a multiomic profile is generated for each single cell in the sample; and 2) 3D mapping: the single cells can be mapped to 3D spatial locations at cellular resolution.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present disclosure relates to systems, methods and compositions for decoding ligand-receptor interactions, for delivering nucleic acids and proteins into target cells and for performing single cell multiomics. Disclosed are engineered lentiviruses displaying ligands that deliver cargo into target cells upon cognate receptor-ligand interaction. Also disclosed are compositions and methods including pMHC or antigen epitopes displaying lentiviruses for identifying pMHC/T-cell receptors and antigen/B-cell receptor interactions.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Provided herein are, inter alia, methods for identifying dysfunctional natural killer (NK) cells in a subject with leukemia. Provided are methods for treating leukemia, including administering to the subject an effective amount of allogeneic NK cells.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Devices, systems, and methods for treating volume overload are disclosed herein. According to some examples, the present technology includes a method comprising delivering a distal portion of an elongate shaft to a treatment site within a vein of an upper chest of a patient, where the treatment site is between a superior vena cava and a left axillary vein. The method can include expanding an occlusive member at the treatment site proximal of an opening to a thoracic duct, thereby blocking blood flow proximal of the occlusive member. The method can further include injecting a contrast agent at the treatment site distal of the occlusive member such that the contrast agent flows retrograde into the thoracic duct.

IPC Classes  ?

• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
• A61F 2/06 - Blood vessels